Patents by Inventor John H. Krystal
John H. Krystal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11554117Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.Type: GrantFiled: July 10, 2018Date of Patent: January 17, 2023Assignee: YALE UNIVERSITYInventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
-
Publication number: 20210294011Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.Type: ApplicationFiled: June 4, 2021Publication date: September 23, 2021Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
-
Publication number: 20210093630Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.Type: ApplicationFiled: December 7, 2020Publication date: April 1, 2021Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
-
Publication number: 20210093629Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.Type: ApplicationFiled: December 7, 2020Publication date: April 1, 2021Inventors: Vladimir Coric, John H. Krystal, Gerad Sanacora
-
Publication number: 20200253894Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).Type: ApplicationFiled: April 9, 2020Publication date: August 13, 2020Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, JR., John H. Krystal
-
Publication number: 20200143922Abstract: Methods and apparatus for providing a treatment recommendation for a patient having a depression disorder. The method comprising receiving patient information including patient responses to each of a plurality of questions provided on a questionnaire, processing, with a trained statistical model, at least some of the received patient information to determine treatment recommendation information for the patient, and transmitting the treatment recommendation information to an electronic device.Type: ApplicationFiled: June 2, 2017Publication date: May 7, 2020Applicants: Yale University, Spring Care, Inc.Inventors: Adam Chekroud, John H. Krystal, Ralitza Gueorguieva, Abhishek Chandra
-
Publication number: 20180318288Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.Type: ApplicationFiled: July 10, 2018Publication date: November 8, 2018Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
-
Patent number: 10052318Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.Type: GrantFiled: May 15, 2014Date of Patent: August 21, 2018Assignee: YALE UNIVERSITYInventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
-
Publication number: 20170360775Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.Type: ApplicationFiled: September 5, 2017Publication date: December 21, 2017Applicant: YALE UNIVERSITYInventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
-
Publication number: 20170181966Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).Type: ApplicationFiled: January 27, 2017Publication date: June 29, 2017Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal
-
Publication number: 20170173039Abstract: The present invention provides compositions and methods comprising talampanel and/or perampanel for treating or preventing an addictive disease or disorder, such as alcoholism, in a subject in need thereof. AMPA receptor (AMPA-Rs) antagonists (i.e., blockers), such as perampanel and talampanel, reduce drug and alcohol seeking behaviors in mammals since activation of glutamatergic AMPA receptors promotes addictive behaviors in mammals.Type: ApplicationFiled: March 26, 2015Publication date: June 22, 2017Inventors: Albert ARIAS, Ismene PETRAKIS, John H. KRYSTAL
-
Publication number: 20170151191Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).Type: ApplicationFiled: December 14, 2016Publication date: June 1, 2017Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, JR., John H. Krystal
-
Patent number: 9592207Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).Type: GrantFiled: June 17, 2014Date of Patent: March 14, 2017Assignees: Icahn School of Medicine at Mount Sinai, Yale University, The United States of America, as represented by The Secretary, Department of Health and Human ServicesInventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal
-
Patent number: 9539220Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).Type: GrantFiled: March 5, 2014Date of Patent: January 10, 2017Assignees: Icahn School of Medicine at Mount Sinai, Yale University, The United States of America, as represented by The Secretary, Department of Health and Human ServicesInventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal
-
Publication number: 20150056308Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).Type: ApplicationFiled: June 17, 2014Publication date: February 26, 2015Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal
-
Publication number: 20140256821Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).Type: ApplicationFiled: March 5, 2014Publication date: September 11, 2014Applicants: Icahn School of Medicine at Mount Sinai, National Institute of Health, Yale University School of MedicineInventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal
-
Publication number: 20140249173Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.Type: ApplicationFiled: May 15, 2014Publication date: September 4, 2014Inventors: Vladimir Coric, John H. Krystal, Gerald Sanacora
-
Patent number: 8785500Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).Type: GrantFiled: March 20, 2007Date of Patent: July 22, 2014Assignees: Icahn School of Medicine at Mount Sinai, Yale University, National Institute of HealthInventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, Jr., John H. Krystal
-
Patent number: 8778979Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.Type: GrantFiled: April 5, 2006Date of Patent: July 15, 2014Assignee: Yale UniversityInventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
-
Patent number: 5447948Abstract: Mazindol and other dopamine and/or noradrenergic reuptake inhibitors are effective to treat negative symptoms in schizophrenia.Type: GrantFiled: May 7, 1992Date of Patent: September 5, 1995Assignee: Yale UniversityInventors: John P. Seibyl, John H. Krystal, Dennis S. Charney
